New FDA commissioner for medical products named
pharmafile | January 28, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | FDA, Robert Califf
US Food and Drug Administration commissioner Margaret Hamburg has appointed industry veteran Dr Robert Califf as the FDA’s deputy commissioner for medical products and tobacco.
Joining in late February Califf will provide leadership to the US regulating body in its centre’s that comprise drug evaluation and research; biologics, devices and radiological health and for tobacco products.
He will also oversee the office of special medical programmes in the office of the commissioner, and manage cross-cutting clinical, scientific and regulatory initiatives in several key areas for the agency – including personalised medicine, orphan drugs, paediatric science, and the advisory committee system.
During his career Califf has led many landmark clinical studies according to the FDA, that adds he is a recognised expert in cardiovascular medicine, health outcomes research and health care quality.
He is currently serving as vice chancellor of clinical and translational research at Duke University, and was the founding director of the Duke Clinical Research Institute, the world’s largest academic research organisation.
“I am delighted to announce this important addition to FDA’s senior leadership team,” says Hamburg. “Dr Califf’s deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalise on, and improve upon, the significant advances we’ve made in medical product development and regulation over the last few years.”
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …
